Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation ...

Tolebrutinib, an experimental drug, slowed disability progression in advanced MS by 31% in a major trial, offering hope for ...

Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...

Cogent Biosciences, Inc. topline results for phase 2/3 studies on bezuclastinib targeting systemic mastocytosis & GIST are ...

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more effectively.

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Relay Therapeutics, Inc.’s RLAY share price has dipped by 6.00%, which has investors questioning if this is right time to buy.

Cogent Biosciences, Inc.’s COGT share price has dipped by 7.73%, which has investors questioning if this is right time to buy ...

In recent years, the ketogenic diet has gained immense popularity for its effectiveness in promoting weight loss and improving overall health. Among the various supplements designed to support those ...

Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

Results of the Phase III HERCULES trial suggest the first potential treatment option for a form of multiple sclerosis.